Sign up to access all valuation multiples
MediClin AG operates hospitals and other medical care centers. The company's reportable operating segments are the Post-acute, Acute, Nursing care, and Service segments. A majority of its revenue is generated from the Post-acute segment, which offers services in the fields of follow-up rehabilitation treatment and curative treatment. Some of the post-acute hospitals also offer services in acute neurology and acute psychosomatics. The Acute segment encompasses medical offerings with a focus on neurology and neurological early rehabilitation as well as psychosomatic medicine, psychiatry, orthopaedics, and internal medicine. The Nursing care segment offers full-time and part-time nursing care as well as daycare, and the Service segment consists of the central services.
1996
9.8K+
LTM Revenue $895M
LTM EBITDA $123M
$560M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
As of November 2025, MediClin reported last 12-month revenue of $895M and EBITDA of $123M.
In the same period, MediClin achieved $32.7M in LTM net income.
See MediClin valuation multiples based on analyst estimatesIn the most recent fiscal year, MediClin reported revenue of $871M and EBITDA of $124M.
MediClin expects next 12-month revenue of XXX and NTM EBITDA of XXX
See MediClin valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $895M | XXX | $871M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $724M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 83% | XXX | XXX | XXX |
| EBITDA | $123M | XXX | $124M | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBIT | $64.3M | XXX | $61.1M | XXX | XXX | XXX |
| EBIT Margin | 7% | XXX | 7% | XXX | XXX | XXX |
| Net Profit | $32.7M | XXX | $28.9M | XXX | XXX | XXX |
| Net Margin | 4% | XXX | 3% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
MediClin has current market cap of EUR 162M (or $189M), and EV of EUR 482M (or $560M).
As of December 4, 2025, MediClin's stock price is EUR 3 (or $4).
See MediClin trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $560M | $189M | XXX | XXX | XXX | XXX | $0.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialMediClin's trades at 0.6x EV/Revenue multiple, and 4.5x EV/EBITDA.
See valuation multiples for MediClin and 15K+ public compsAs of December 4, 2025, MediClin has market cap of $189M and EV of $560M.
Equity research analysts estimate MediClin's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
MediClin has a P/E ratio of 5.8x.
| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $189M | XXX | $189M | XXX | XXX | XXX |
| EV (current) | $560M | XXX | $560M | XXX | XXX | XXX |
| EV/Revenue | 0.6x | XXX | 0.6x | XXX | XXX | XXX |
| EV/EBITDA | 4.6x | XXX | 4.5x | XXX | XXX | XXX |
| EV/EBIT | 8.7x | XXX | 9.2x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 5.8x | XXX | 6.5x | XXX | XXX | XXX |
| EV/FCF | 8.7x | XXX | 13.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialMediClin's last 12 month revenue growth is 3%
MediClin's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
MediClin's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
MediClin's rule of X is 21% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for MediClin and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 3% | XXX | 3% | XXX | XXX | XXX |
| EBITDA Margin | 14% | XXX | 14% | XXX | XXX | XXX |
| EBITDA Growth | 2% | XXX | 2% | XXX | XXX | XXX |
| Rule of 40 | 17% | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 21% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 0% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 76% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Burjeel Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| PureHealth | XXX | XXX | XXX | XXX | XXX | XXX |
| Integral Diagnostics | XXX | XXX | XXX | XXX | XXX | XXX |
| Monash IVF Group | XXX | XXX | XXX | XXX | XXX | XXX |
| Ramsay Health | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
MediClin acquired XXX companies to date.
Last acquisition by MediClin was XXXXXXXX, XXXXX XXXXX XXXXXX . MediClin acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was MediClin founded? | MediClin was founded in 1996. |
| Where is MediClin headquartered? | MediClin is headquartered in Germany. |
| How many employees does MediClin have? | As of today, MediClin has 9.8K+ employees. |
| Is MediClin publicy listed? | Yes, MediClin is a public company listed on ETR. |
| What is the stock symbol of MediClin? | MediClin trades under MED ticker. |
| When did MediClin go public? | MediClin went public in 2000. |
| Who are competitors of MediClin? | Similar companies to MediClin include e.g. Burjeel Holdings, PureHealth, Integral Diagnostics, Monash IVF Group. |
| What is the current market cap of MediClin? | MediClin's current market cap is $189M |
| What is the current revenue of MediClin? | MediClin's last 12 months revenue is $895M. |
| What is the current revenue growth of MediClin? | MediClin revenue growth (NTM/LTM) is 3%. |
| What is the current EV/Revenue multiple of MediClin? | Current revenue multiple of MediClin is 0.6x. |
| Is MediClin profitable? | Yes, MediClin is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of MediClin? | MediClin's last 12 months EBITDA is $123M. |
| What is MediClin's EBITDA margin? | MediClin's last 12 months EBITDA margin is 14%. |
| What is the current EV/EBITDA multiple of MediClin? | Current EBITDA multiple of MediClin is 4.6x. |
| What is the current FCF of MediClin? | MediClin's last 12 months FCF is $64.6M. |
| What is MediClin's FCF margin? | MediClin's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of MediClin? | Current FCF multiple of MediClin is 8.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
